{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T01:10:17Z","timestamp":1707527417639},"reference-count":98,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2006,4,1]],"date-time":"2006-04-01T00:00:00Z","timestamp":1143849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Critical Care Clinics"],"published-print":{"date-parts":[[2006,4]]},"DOI":"10.1016\/j.ccc.2006.02.008","type":"journal-article","created":{"date-parts":[[2007,1,10]],"date-time":"2007-01-10T15:08:25Z","timestamp":1168441705000},"page":"199-219","source":"Crossref","is-referenced-by-count":2,"title":["Contemporary Issues in the Pharmacologic Management of Acute Heart Failure"],"prefix":"10.1016","volume":"22","author":[{"given":"Tien M.H.","family":"Ng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amardeep K.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph F.","family":"Dasta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandre","family":"Mebazaa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ccc.2006.02.008_bib2","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1016\/j.jacc.2005.07.012","volume":"46","author":"Bonow","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ccc.2006.02.008_bib3","series-title":"Heart disease and stroke statistics\u20142005 update","year":"2005"},{"key":"10.1016\/j.ccc.2006.02.008_bib4","unstructured":"HCUPnet. Healthcare Cost and Utilization Project. Agency for Healthcare Resource and Quality. Rockville (MD). Available at: http:\/\/hcup.ahrq.gov\/HCUPnet.asp"},{"key":"10.1016\/j.ccc.2006.02.008_bib5","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/S1567-4215(05)80220-6","article-title":"Temporal changes in US hospitalizations, costs and clinical characteristics of patients with severe acute decompensated heart failure","volume":"4","author":"Delgado","year":"2005","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ccc.2006.02.008_bib6","first-page":"e345","article-title":"Comparison of patients with primary vs secondary heart failure from a database of 2.5 million admissions: implications for coding and reimbursement policies","volume":"111","author":"Feldman","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.ccc.2006.02.008_bib7","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s10741-005-6127-6","article-title":"Overview of acutely decompensated congestive heart failure (ADHF): a report from the ADHERE registry","volume":"9","author":"Fonarow","year":"2004","journal-title":"Heart Fail Rev"},{"issue":"suppl","key":"10.1016\/j.ccc.2006.02.008_bib8","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.amjcard.2005.07.015","article-title":"Definition and epidemiology of acute heart failure syndromes","volume":"96","author":"Nieminen","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ccc.2006.02.008_bib9","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ahj.2004.08.005","article-title":"Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE)","volume":"149","author":"Adams","year":"2005","journal-title":"Am Heart J"},{"key":"10.1016\/j.ccc.2006.02.008_bib10","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1001\/jama.293.5.572","article-title":"Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis","volume":"293","author":"Fonarow","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.ccc.2006.02.008_bib11","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1161\/01.CIR.100.9.999","article-title":"Mechanisms and models in heart failure: a combinatorial approach","volume":"100","author":"Mann","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.ccc.2006.02.008_bib12","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S1388-9842(99)00015-X","article-title":"Tailored therapy to hemodynamic goals for advanced heart failure","volume":"1","author":"Stevenson","year":"1999","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ccc.2006.02.008_bib13","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/0735-1097(92)90167-L","article-title":"The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure","volume":"20","author":"Packer","year":"1992","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ccc.2006.02.008_bib14","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1056\/NEJM199908193410806","article-title":"Hormones and hemodynamics in heart failure","volume":"341","author":"Schrier","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ccc.2006.02.008_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-103-1-1","article-title":"Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure: activation of the neurohumoral axis","volume":"103","author":"Francis","year":"1985","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ccc.2006.02.008_bib16","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1161\/hc1102.105264","article-title":"BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy","volume":"105","author":"Gottlieb","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.ccc.2006.02.008_bib17","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s11897-004-0020-9","article-title":"Cardiorenal syndrome in decompensated heart failure: prognostic and therapeutic implications","volume":"1","author":"Boerrigter","year":"2004","journal-title":"Curr Heart Fail Rep"},{"key":"10.1016\/j.ccc.2006.02.008_bib18","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1054\/jcaf.2002.125368","article-title":"The potential of brain natriuretic peptide as a biomarker for New York Heart Association class during the outpatient treatment of heart failure","volume":"8","author":"Lee","year":"2002","journal-title":"J Card Fail"},{"key":"10.1016\/j.ccc.2006.02.008_bib19","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/S0008-6363(01)00320-0","article-title":"Measurement of plasma brain natriuretic peptide level as a guide for cardiac overload","volume":"51","author":"Hirata","year":"2001","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.ccc.2006.02.008_bib20","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/S0735-1097(00)01157-8","article-title":"A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study","volume":"37","author":"Cheng","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ccc.2006.02.008_bib21","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1136\/bmj.324.7352.1498","article-title":"Reliability of N-terminal pro-brain natriuretic peptide assay in diagnosis of heart failure: cohort study in representative and high risk community populations","volume":"324","author":"Hobbs","year":"2002","journal-title":"BMJ"},{"key":"10.1016\/j.ccc.2006.02.008_bib22","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1136\/hrt.2003.014258","article-title":"Reliability of N-terminal proBNP assay in diagnosis of left ventricular systolic dysfunction within representative and high risk populations","volume":"90","author":"Hobbs","year":"2004","journal-title":"Heart"},{"key":"10.1016\/j.ccc.2006.02.008_bib23","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1067\/mhj.2001.113215","article-title":"Utility of B-natriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction","volume":"141","author":"Maisel","year":"2001","journal-title":"Am Heart J"},{"key":"10.1016\/j.ccc.2006.02.008_bib24","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/S0140-6736(94)92690-5","article-title":"Plasma brain natriuretic peptide in assessment of acute dyspnoea","volume":"343","author":"Davis","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.ccc.2006.02.008_bib25","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1161\/01.CIR.0000025242.79963.4C","article-title":"B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from Breathing Not Properly (BNP) Multinational Study","volume":"106","author":"McCullough","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.ccc.2006.02.008_bib26","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1161\/hc0502.103010","article-title":"Utility of B-natriuretic peptide in detecting diastolic dysfunction: comparison with Doppler velocity recordings","volume":"105","author":"Lubien","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.ccc.2006.02.008_bib27","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1161\/01.CIR.97.19.1921","article-title":"Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction","volume":"97","author":"Richards","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.ccc.2006.02.008_bib28","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.ehj.2003.10.030","article-title":"The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT","volume":"25","author":"Latini","year":"2004","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ccc.2006.02.008_bib29","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1161\/01.CIR.0000036747.68104.AC","article-title":"Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT)","volume":"106","author":"Latini","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.ccc.2006.02.008_bib30","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/S0140-6736(00)02060-2","article-title":"Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations","volume":"355","author":"Troughton","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.ccc.2006.02.008_bib31","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/S0735-1097(98)00609-3","article-title":"Effect of angiotensin converting enzyme inhibition on sudden cardiac death in patients following acute myocardial infarction: a meta-analysis of randomized clinical trials","volume":"33","author":"Domanski","year":"1999","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ccc.2006.02.008_bib32","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S0002-9343(02)01121-X","article-title":"B-type natriuretic peptide as a marker of the effects of enalapril in patients with heart failure","volume":"112","author":"Yoshimura","year":"2002","journal-title":"Am J Med"},{"issue":"6 pt 1","key":"10.1016\/j.ccc.2006.02.008_bib33","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/S0002-8703(99)70079-7","article-title":"Titration of vasodilator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration: randomized comparison of the hemodynamic and neuroendocrine effects of tailored versus empirical therapy","volume":"138","author":"Murdoch","year":"1999","journal-title":"Am Heart J"},{"issue":"suppl 3","key":"10.1016\/j.ccc.2006.02.008_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1527-5299.2004.03271.x","article-title":"BNP Consensus Panel 2004: a clinical approach for the diagnostic, prognostic, screening, treatment monitoring, and therapeutic roles of natriuretic peptides in cardiovascular diseases","volume":"10","author":"Silver","year":"2004","journal-title":"Congest Heart Fail"},{"key":"10.1016\/j.ccc.2006.02.008_bib35","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1054\/jcaf.2002.0805288","article-title":"Role of brain natriuretic peptide in the diagnosis and management of heart failure: current concepts","volume":"8","author":"Latini","year":"2002","journal-title":"J Card Fail"},{"key":"10.1016\/j.ccc.2006.02.008_bib36","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1136\/hrt.2005.063784","article-title":"Clinical usefulness of B-type natriuretic peptide measurement: present and future perspectives","volume":"91","author":"Bettencourt","year":"2005","journal-title":"Heart"},{"key":"10.1016\/j.ccc.2006.02.008_bib37","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1001\/jama.294.13.1625","article-title":"Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial","volume":"294","author":"Binanay","year":"2005","journal-title":"JAMA"},{"issue":"suppl 2","key":"10.1016\/j.ccc.2006.02.008_bib38","first-page":"S7","article-title":"The treatment targets in acute decompensated heart failure","volume":"2","author":"Fonarow","year":"2001","journal-title":"Rev Cardiovasc Med"},{"key":"10.1016\/j.ccc.2006.02.008_bib39","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1001\/jama.287.12.1541","article-title":"Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial","volume":"287","author":"Cuffe","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.ccc.2006.02.008_bib40","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1161\/01.CIR.56.3.468","article-title":"The cardiovascular effects of the continuous infusion of dobutamine in patients with severe cardiac failure","volume":"56","author":"Leier","year":"1977","journal-title":"Circulation"},{"key":"10.1016\/j.ccc.2006.02.008_bib41","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/0002-8703(86)90475-8","article-title":"Intermittent, ambulatory dobutamine infusions in patients with severe congestive heart failure","volume":"112","author":"Krell","year":"1986","journal-title":"Am Heart J"},{"key":"10.1016\/j.ccc.2006.02.008_bib42","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1056\/NEJM199111213252103","article-title":"Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group","volume":"325","author":"Packer","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ccc.2006.02.008_bib43","doi-asserted-by":"crossref","first-page":"35B","DOI":"10.1016\/j.amjcard.2004.01.004","article-title":"Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial: carvedilol in severe heart failure","volume":"93","author":"Fowler","year":"2004","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ccc.2006.02.008_bib44","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1001\/jama.289.6.712","article-title":"Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS Study","volume":"289","author":"Krum","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.ccc.2006.02.008_bib45","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1056\/NEJM199808063390607","article-title":"Diuretic therapy","volume":"339","author":"Brater","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ccc.2006.02.008_bib46","first-page":"197","article-title":"Diuretic therapy in congestive heart failure","volume":"6","author":"Brater","year":"2000","journal-title":"Congest Heart Fail"},{"key":"10.1016\/j.ccc.2006.02.008_bib47","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/0735-1097(96)00161-1","article-title":"Diuretic efficacy of high dose furosemide in severe heart failure: bolus injection versus continuous infusion","volume":"28","author":"Dormans","year":"1996","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ccc.2006.02.008_bib48","first-page":"121","article-title":"Diuretic effects of furosemide infusion versus bolus injection in congestive heart failure","volume":"18","author":"Pivac","year":"1998","journal-title":"Int J Clin Pharmacol Res"},{"key":"10.1016\/j.ccc.2006.02.008_bib49","doi-asserted-by":"crossref","first-page":"361","DOI":"10.3109\/00365519709099409","article-title":"Effect of bolus injection versus continuous infusion of furosemide on diuresis and neurohormonal activation in patients with severe congestive heart failure","volume":"57","author":"Aaser","year":"1997","journal-title":"Scand J Clin Lab Invest"},{"key":"10.1016\/j.ccc.2006.02.008_bib50","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1378\/chest.102.3.725","article-title":"Intermittent administration of furosemide vs continuous infusion preceded by a loading dose for congestive heart failure","volume":"102","author":"Lahav","year":"1992","journal-title":"Chest"},{"key":"10.1016\/j.ccc.2006.02.008_bib51","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1093\/eurheartj\/ehi176","article-title":"Diuretic usage in heart failure: a continuing conundrum in 2005","volume":"26","author":"Gupta","year":"2005","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ccc.2006.02.008_bib52","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1056\/NEJMoa022021","article-title":"Nitroprusside in critically ill patients with left ventricular dysfunction and aortic stenosis","volume":"348","author":"Khot","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ccc.2006.02.008_bib53","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.amjcard.2003.09.051","article-title":"Comparison of effects on left ventricular filling pressure of intravenous nesiritide and high-dose nitroglycerin in patients with decompensated heart failure","volume":"93","author":"Elkayam","year":"2004","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ccc.2006.02.008_bib54","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1001\/jama.287.12.1531","article-title":"Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial","volume":"287","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.ccc.2006.02.008_bib55","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0735-1097(99)00184-9","article-title":"Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failure: a randomized, double-blind, placebo-controlled clinical trial. Natrecor Study Group","volume":"34","author":"Mills","year":"1999","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ccc.2006.02.008_bib56","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1056\/NEJM200007273430403","article-title":"Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group","volume":"343","author":"Colucci","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ccc.2006.02.008_bib57","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0002-9149(01)01581-8","article-title":"Comparison of the occurrence of ventricular arrhythmias in patients with acutely decompensated congestive heart failure receiving dobutamine versus nesiritide therapy","volume":"88","author":"Burger","year":"2001","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ccc.2006.02.008_bib58","series-title":"Nesiritide (Natrecor) package insert","author":"Scios","year":"2005"},{"key":"10.1016\/j.ccc.2006.02.008_bib59","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1161\/01.CIR.0000159340.93220.E4","article-title":"Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure","volume":"111","author":"Sackner-Bernstein","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.ccc.2006.02.008_bib60","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1001\/jama.293.15.1900","article-title":"Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials","volume":"293","author":"Sackner-Bernstein","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.ccc.2006.02.008_bib61","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jacc.2005.03.051","article-title":"In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE)","volume":"46","author":"Abraham","year":"2005","journal-title":"J Am Coll Cardiol"},{"issue":"suppl","key":"10.1016\/j.ccc.2006.02.008_bib62","first-page":"II-675","article-title":"Nesiritide may diminish the increased acute mortality risk associated with worsening renal function","volume":"112","author":"Elkayam","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.ccc.2006.02.008_bib63","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1067\/mhj.2001.117606","article-title":"Inotropic therapy for heart failure: an evidence-based approach","volume":"142","author":"Felker","year":"2001","journal-title":"Am Heart J"},{"key":"10.1016\/j.ccc.2006.02.008_bib64","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1056\/NEJM199702203360801","article-title":"The effect of digoxin on mortality and morbidity in patients with heart failure","volume":"336","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ccc.2006.02.008_bib65","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1161\/01.CIR.96.9.2920","article-title":"Hibernating myocardium: an incomplete adaptation to ischemia","volume":"96","author":"Elsasser","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.ccc.2006.02.008_bib66","first-page":"783","article-title":"The inotropic and hemodynamic effects of intravenous milrinone when reflex adrenergic stimulation is suppressed by beta-adrenergic blockade","volume":"16","author":"Travill","year":"1994","journal-title":"Clin Ther"},{"key":"10.1016\/j.ccc.2006.02.008_bib67","doi-asserted-by":"crossref","first-page":"14B","DOI":"10.1016\/j.amjcard.2005.03.004","article-title":"Current treatments and novel pharmacologic treatments for hyponatremia in congestive heart failure","volume":"95","author":"Goldsmith","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ccc.2006.02.008_bib68","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0008-6363(02)00244-4","article-title":"Neurohormonal antagonism in heart failure; beneficial effects of vasopressin V(1a) and V(2) receptor blockade and ACE inhibition","volume":"54","author":"Naitoh","year":"2002","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.ccc.2006.02.008_bib69","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0014-2999(96)00940-5","article-title":"Pharmacological profile of YM087, a novel nonpeptide dual vasopressin V1A and V2 receptor antagonist, in dogs","volume":"321","author":"Yatsu","year":"1997","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.ccc.2006.02.008_bib70","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1001\/jama.291.16.1963","article-title":"Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial","volume":"291","author":"Gheorghiade","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.ccc.2006.02.008_bib71","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1161\/hc4501.099313","article-title":"Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure","volume":"104","author":"Udelson","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.ccc.2006.02.008_bib72","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1592\/phco.24.14.1366.43145","article-title":"Levosimendan, a new calcium-sensitizing inotrope for heart failure","volume":"24","author":"Ng","year":"2004","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ccc.2006.02.008_bib73","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/j.1742-1241.2003.tb10517.x","article-title":"Levosimendan: a new dual-action drug in the treatment of acute heart failure","volume":"57","author":"Mebazaa","year":"2003","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.ccc.2006.02.008_bib74","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1053\/euhj.2001.3158","article-title":"Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction: a randomized, placebo-controlled, double-blind study (RUSSLAN)","volume":"23","author":"Moiseyev","year":"2002","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ccc.2006.02.008_bib75","first-page":"565","article-title":"Levosimendan: dual mechanisms for acute heart failure and beyond?","volume":"53","author":"Ng","year":"2005","journal-title":"Min Cardioangiol"},{"key":"10.1016\/j.ccc.2006.02.008_bib76","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S0140-6736(02)09455-2","article-title":"Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial","volume":"360","author":"Follath","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.ccc.2006.02.008_bib77","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.ejheart.2004.07.007","article-title":"Clinical trials update from the European Society of Cardiology Heart Failure meeting: SHAPE, BRING-UP 2 VAS, COLA II, FOSIDIAL, BETACAR, CASINO and meta-analysis of cardiac resynchronisation therapy","volume":"6","author":"Coletta","year":"2004","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ccc.2006.02.008_bib78","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/j.1440-1681.1988.tb01059.x","article-title":"Atrial natriuretic factor in human pathophysiology","volume":"15","author":"Crozier","year":"1988","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.ccc.2006.02.008_bib79","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1097\/01.fjc.0000177980.83810.2e","article-title":"Inhibition of aldosterone and endothelin-1 by carperitide was attenuated with more than 1 week of infusion in patients with congestive heart failure","volume":"46","author":"Ishikawa","year":"2005","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.ccc.2006.02.008_bib80","first-page":"209","article-title":"Urodilatin, a new therapy to prevent kidney failure after heart transplantation","volume":"12","author":"Hummel","year":"1993","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.ccc.2006.02.008_bib81","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/0002-8703(95)90328-3","article-title":"Efficacy of prolonged infusion of urodilatin [ANP-(95\u2013126)] in patients with congestive heart failure","volume":"129","author":"Elsner","year":"1995","journal-title":"Am Heart J"},{"key":"10.1016\/j.ccc.2006.02.008_bib82","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/S0008-6363(01)00331-5","article-title":"The renal urodilatin system: clinical implications","volume":"51","author":"Forssmann","year":"2001","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.ccc.2006.02.008_bib83","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1253\/circj.69.283","article-title":"Multicenter prospective investigation on efficacy and safety of carperitide for acute heart failure in the \u2018real world\u2019 of therapy","volume":"69","author":"Suwa","year":"2005","journal-title":"Circ J"},{"key":"10.1016\/j.ccc.2006.02.008_bib84","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1536\/jhj.42.271","article-title":"Usefulness of carperitide for the treatment of refractory heart failure due to severe acute myocardial infarction","volume":"42","author":"Kikuchi","year":"2001","journal-title":"Jpn Heart J"},{"key":"10.1016\/j.ccc.2006.02.008_bib85","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0735-1097(99)00532-X","article-title":"Effects of BG9719 (CVT-124), an A1-adenosine receptor antagonist, and furosemide on glomerular filtration rate and natriuresis in patients with congestive heart failure","volume":"35","author":"Gottlieb","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ccc.2006.02.008_bib86","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.2165\/00003495-200161100-00002","article-title":"Renal effects of adenosine A1-receptor antagonists in congestive heart failure","volume":"61","author":"Gottlieb","year":"2001","journal-title":"Drugs"},{"key":"10.1016\/j.ccc.2006.02.008_bib87","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1023\/B:UROL.0000034633.95171.64","article-title":"Ultrafiltration in the treatment of severe congestive heart failure","volume":"36","author":"Grapsa","year":"2004","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.ccc.2006.02.008_bib88","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1159\/000047398","article-title":"Clinical benefit and approach of ultrafiltration in acute heart failure","volume":"96","author":"Sharma","year":"2001","journal-title":"Cardiology"},{"issue":"suppl","key":"10.1016\/j.ccc.2006.02.008_bib89","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1093\/ajhp\/60.suppl_4.S21","article-title":"Clinical and economic impact of nesiritide","volume":"60","author":"Peacock","year":"2003","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.ccc.2006.02.008_bib90","first-page":"1476","article-title":"Incidence and potential economic impact of hyponatremia in hospitalized patients","volume":"25","author":"Long","year":"2005","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ccc.2006.02.008_bib91","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1067\/mhj.2001.119610","article-title":"Comparison of dobutamine-based and milrinone-based therapy for advanced decompensated congestive heart failure: hemodynamic efficacy, clinical outcome, and economic impact","volume":"142","author":"Yamani","year":"2001","journal-title":"Am Heart J"},{"key":"10.1016\/j.ccc.2006.02.008_bib92","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S1388-9842(02)00246-5","article-title":"Intravenous levosimendan treatment is cost-effective compared with dobutamine in severe low-output heart failure: an analysis based on the international LIDO trial","volume":"5","author":"Cleland","year":"2003","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ccc.2006.02.008_bib93","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S0002-9149(03)00742-2","article-title":"Economic implications of nesiritide versus dobutamine in the treatment of patients with acutely decompensated congestive heart failure","volume":"92","author":"de Lissovoy","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ccc.2006.02.008_bib94","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1592\/phco.2006.26.1.34","article-title":"Pharmacoeconomic modeling of nesiritide versus dobutamine for decompensated heart failure","volume":"26","author":"Gerhard","year":"2006","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ccc.2006.02.008_bib95","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1592\/phco.24.13.1137.38081","article-title":"Impact of nesiritide on health care resource utilization and complications in patients with decompensated heart failure","volume":"24","author":"Lenz","year":"2004","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ccc.2006.02.008_bib96","doi-asserted-by":"crossref","first-page":"S178","DOI":"10.1016\/j.cardfail.2005.06.334","article-title":"Early therapy with nesiritide in hospitalized patients with acute decompensated heart failure associated with reduced costs: a Markov analysis","volume":"11","author":"Blackburn","year":"2005","journal-title":"J Card Fail"},{"key":"10.1016\/j.ccc.2006.02.008_bib97","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jemermed.2005.01.024","article-title":"Observation unit treatment of heart failure with nesiritide: results from the proaction trial","volume":"29","author":"Peacock","year":"2005","journal-title":"J Emerg Med"},{"key":"10.1016\/j.ccc.2006.02.008_bib98","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1345\/aph.1D481","article-title":"Guidelines for acute decompensated heart failure treatment","volume":"38","author":"DiDomenico","year":"2004","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.ccc.2006.02.008_bib99","first-page":"1435","article-title":"Treatment guidelines for acute decompensated heart failure associated with improved outcomes","volume":"25","author":"Eyrich","year":"2005","journal-title":"Pharmacotherapy"}],"container-title":["Critical Care Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749070406000091?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749070406000091?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:57:59Z","timestamp":1707526679000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0749070406000091"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,4]]},"references-count":98,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2006,4]]}},"alternative-id":["S0749070406000091"],"URL":"https:\/\/doi.org\/10.1016\/j.ccc.2006.02.008","relation":{},"ISSN":["0749-0704"],"issn-type":[{"value":"0749-0704","type":"print"}],"subject":[],"published":{"date-parts":[[2006,4]]}}}